Scilex (SCLX) announced that it has entered into an amendment to its existing license agreement with Romeg Therapeutics, entered into in June 2022, for ex-U.S. rights to Gloperba. Romeg had previously granted Scilex an exclusive license to commercialize Gloperba only in the U.S. Gloperba is taken orally like cough syrup. The dosage of 0.6mg per 5ml can fill that important void in treatment where patients may have difficulty swallowing pills. It can also provide more adjustable dosing, titration and dose-reduction options in specific populations, especially for gout patients with renal or hepatic impairment and reduce side effects with the goal to improve patient convenience and disease management.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5%
- Scilex Adjusts Record Date for Preferred Stock Dividend
- Scilex announces change in record date for dividend of preferred stock
- Scilex Holding Co options imply 15.0% move in share price post-earnings
- Scilex announces early installment payment on senior secured promissory note